RESULTS ROUND-UP: Hologic, Thermo and Varian on the up, Qiagen falls short
This article was originally published in Clinica
Hologic’s turnaround is “well underway,” as the firm beat analyst expectations for both revenues and earnings during its first quarter, according to Jefferies analyst Raj Denhoy. Q1 sales of $652.8m increased 7% year-on-year and were $20m above analyst consensus; while adjusted earnings of $0.39 per share beat their predictions of $0.36 per share.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.